A.R.T. Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

A.R.T. Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,145	Closed	-$167K	–	1398
2019 Q3	$167K	Buy	+1,145	New	+$199K	0.01%	1205

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

A.R.T. Advisors's CRBP Position: Q4 2019 in Review

A.R.T. Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 1,145 shares — an estimated $167K sold.

A.R.T. Advisors first reported a position in CRBP in Q3 2019 and held it in 1 quarter. The position peaked at $167K in Q3 2019. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

A.R.T. Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 1,145 Corbus Pharmaceuticals shares in Q4 2019, an estimated $167K.
A.R.T. Advisors first reported a position in Corbus Pharmaceuticals in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Corbus Pharmaceuticals position peaked at $167K in Q3 2019.
105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.